000280973 001__ 280973
000280973 005__ 20250921002018.0
000280973 0247_ $$2doi$$a10.4081/ejtm.2025.13956
000280973 0247_ $$2pmid$$apmid:40438995
000280973 0247_ $$2pmc$$apmc:PMC12265423
000280973 0247_ $$2ISSN$$a2037-7452
000280973 0247_ $$2ISSN$$a1120-9992
000280973 0247_ $$2ISSN$$a2037-7460
000280973 0247_ $$2ISSN$$a2385-2852
000280973 0247_ $$2altmetric$$aaltmetric:177583004
000280973 037__ $$aDZNE-2025-01055
000280973 041__ $$aEnglish
000280973 082__ $$a610
000280973 1001_ $$aDowling, Paul$$b0
000280973 245__ $$aSerum protein biomarker signature of Duchenne muscular dystrophy.
000280973 260__ $$aPadova$$bUnipress$$c2025
000280973 3367_ $$2DRIVER$$aarticle
000280973 3367_ $$2DataCite$$aOutput Types/Journal article
000280973 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1756891458_1279
000280973 3367_ $$2BibTeX$$aARTICLE
000280973 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000280973 3367_ $$00$$2EndNote$$aJournal Article
000280973 520__ $$aIn contrast to invasive skeletal muscle biopsies and the associated complexity of tissue sampling techniques and potential detrimental side effects, the alternative application of liquid biopsy procedures has considerable advantages concerning minimal invasiveness, repeated sampling options, assay robustness and cost effectiveness. This article outlines the current status of serum biomarkers used for diagnosing and characterizing Duchenne muscular dystrophy (DMD), a primary muscle wasting disease of early childhood due to primary abnormalities in the extremely large DMD gene. Reviewed are important aspects of the discovery, characterization and diagnostic value of biofluid-based protein markers of dystrophinopathy. This includes an overview of traditional general skeletal muscle damage markers, such as creatine kinase, myoglobin and lactate dehydrogenase, which have been used for many decades in clinical applications to evaluate patients with muscular weakness. In addition, this article outlines the biochemical identification of novel biomarker candidates focusing on the usage of mass spectrometry-based proteomic surveys to establish comprehensive profiles of protein alterations in dystrophinopathy. Pathoproteomic serum markers of myonecrosis with great potential for improved patient screening, differential diagnosis, stage-specific prognosis and therapeutic monitoring include specific isoforms of muscle-derived cytosolic proteins, such as carbonic anhydrase isoform CA3 and fatty acid binding protein FABP3, as well as sarcomeric proteins, including specific isoforms of myosin light chain, myosin binding protein, troponin, and myomesin, in addition to peptide fragments derived from the giant protein titin. Biofluid-associated marker proteins of reactive myofibrosis include the extracellular matrix proteins fibronectin, osteopontin, collagen and matrix-metalloproteinases.
000280973 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000280973 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000280973 7001_ $$aNegroni, Elisa$$b1
000280973 7001_ $$aTrollet, Capucine$$b2
000280973 7001_ $$0P:(DE-2719)9000835$$aZweyer, Margit$$b3$$udzne
000280973 7001_ $$aSwandulla, Dieter$$b4
000280973 7001_ $$aOhlendieck, Kay$$b5
000280973 773__ $$0PERI:(DE-600)2545577-1$$a10.4081/ejtm.2025.13956$$gVol. 35, no. 2$$n2$$p13956$$tEuropean journal of translational myology$$v35$$x2037-7452$$y2025
000280973 8564_ $$uhttps://pub.dzne.de/record/280973/files/DZNE-2025-01055.pdf$$yOpenAccess
000280973 8564_ $$uhttps://pub.dzne.de/record/280973/files/DZNE-2025-01055.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000280973 909CO $$ooai:pub.dzne.de:280973$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000280973 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000835$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000280973 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000280973 9141_ $$y2025
000280973 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-11
000280973 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-11
000280973 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J TRANSL MYOL : 2022$$d2024-12-11
000280973 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-08-12T14:11:10Z
000280973 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-08-12T14:11:10Z
000280973 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-11
000280973 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-11
000280973 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-11
000280973 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2024-12-11
000280973 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000280973 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-11
000280973 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-11
000280973 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-11
000280973 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-11
000280973 9201_ $$0I:(DE-2719)1013032$$kAG Salomoni$$lNuclear Function in CNS Pathophysiology$$x0
000280973 980__ $$ajournal
000280973 980__ $$aVDB
000280973 980__ $$aUNRESTRICTED
000280973 980__ $$aI:(DE-2719)1013032
000280973 9801_ $$aFullTexts